↓ Skip to main content

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

Overview of attention for article published in Cancer Research, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
1 news outlet
twitter
7 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
21 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort
Published in
Cancer Research, January 2017
DOI 10.1158/0008-5472.can-16-1524
Pubmed ID
Authors

Renée T Fortner, Helena Schock, Rudolf Kaaks, Matti Lehtinen, Eero Pukkala, Hans-Åke Lakso, Minna Tanner, Raija Kallio, Heikki Joensuu, Jaana Korpela, Adetunji T Toriola, Göran Hallmans, Kjell Grankvist, Anne Zeleniuch-Jacquotte, Paolo Toniolo, Eva Lundin, Heljä-Marja Surcel

Abstract

Human chorionic gonadotropin (hCG) is necessary for the maintenance of early pregnancy and promotes normal breast cell differentiation. Administered hCG reduces risk of carcinogen-induced breast cancer in animal models, and higher circulating hCG concentrations were associated with significantly lower long-term risk of breast cancer in a prior nested case-control study. In this study, we investigated early pregnancy hCG concentrations and subsequent breast cancer risk. We conducted a nested case-control study with 1,191 cases and 2,257 controls (matched on age and date at blood collection) in the Finnish Maternity Cohort (FMC), a cohort with serum samples from 98% of pregnancies registered in Finland since 1983. This study included women with a serum sample collected early (<140 days gestation) in their first pregnancy resulting in a live, term birth. Breast cancer cases were identified via the Finnish Cancer Registry. Age at breast cancer diagnosis ranged from 22-58 years (mean: 41 years). hCG was measured using a solidphase competitive chemiluminescence assay. Odds ratios (ORs) were calculated using conditional logistic regression. We observed no association between hCG and breast cancer risk, overall (Quartile 4 vs. 1, OR: 1.14 95% confidence interval [0.94-1.39], by estrogen and progesterone receptor status, or by ages at first term birth or diagnosis. Associations did not differ by time between pregnancy and diagnosis (e.g., <5 years, ORQ4 vs. Q1: 1.10 [0.64-1.89]; {greater than or equal to}15 years, ORQ4 vs. Q1: 1.36 [0.86-2.13]; pheterogeneity=0.62). This large prospective study does not support an inverse relationship between early pregnancy serum hCG concentrations and breast cancer risk.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 5%
Unknown 20 95%

Demographic breakdown

Readers by professional status Count As %
Professor 5 24%
Librarian 2 10%
Student > Ph. D. Student 2 10%
Student > Postgraduate 2 10%
Student > Master 2 10%
Other 4 19%
Unknown 4 19%
Readers by discipline Count As %
Medicine and Dentistry 8 38%
Nursing and Health Professions 3 14%
Biochemistry, Genetics and Molecular Biology 2 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Social Sciences 1 5%
Other 1 5%
Unknown 5 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2017.
All research outputs
#2,371,607
of 22,899,952 outputs
Outputs from Cancer Research
#1,823
of 17,897 outputs
Outputs of similar age
#51,016
of 420,417 outputs
Outputs of similar age from Cancer Research
#33
of 230 outputs
Altmetric has tracked 22,899,952 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,897 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,417 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 230 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.